Novo Ventures and Sanofi Ventures, the venture arms of pharmaceutical companies Novo Nordisk and Sanofi respectively, have led a $83m series-C round for Netherlands-based T-cell cancer therapy company Lava Therapeutics.
Novo Ventures and Sanofi Ventures, the venture arms of pharmaceutical companies Novo Nordisk and Sanofi respectively, have led a $83m series-C round for Netherlands-based T-cell cancer therapy company Lava Therapeutics.